WHO's Global Tuberculosis Programme develops evidence-informed policy as new evidence becomes available. As many of the new policy recommendations on treatment and prevention are at the cutting edge of science, important practical questions remain related to implementation. These include important aspects to optimize TB medicine dosing strategies and drug delivery approaches among children and adults, for which several studies have been conducted or are ongoing. However, these are beyond the scope of the WHO guideline development process and require additional evidence and critical evaluation from technical experts.

This Technical Advisory Group on dosing of TB medicines for adults and children has been established to provide an independent evaluation and advice to WHO on dosing issues related to TB medicines for all ages and for all indications, aligned to WHO recommendations. 

The Advisory Group is composed of 20 members who have a range of technical knowledge, skills and experience in clinical pharmacology, pharmacokinetics/pharmacodynamics, pharmacometrics, clinical research and clinical medicine, including paediatricians with experience in tuberculosis. The group also includes experts from national TB programmes and civil society and community representatives.

In its capacity as an advisory body to WHO, the Advisory Group shall have the following functions:

• to provide an independent evaluation and advice to WHO on scientific and technical aspects of dosing of anti-tuberculosis medicines for children and adults with all forms of TB, aligned to WHO recommendations and based on the latest available scientific evidence with the aim to optimize the dosing of TB medicines and the operational guidance on their use by country programmes; and
• to advise WHO on the new developments in the dosing and drug delivery approaches of medicines used in TB care.